Synopsis
Synopsis
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
1. Trimethylene
1. Trimethylene
2. 75-19-4
3. Ciclopropano
4. Cyclopropanum
5. Zyklopropan
6. Trimethylene (cyclic)
7. Cyclopropan
8. Chebi:30365
9. 99tb643425
10. Cyclopropane [inn]
11. Cyclopropanum [inn-latin]
12. Ciclopropano [inn-spanish]
13. Hsdb 812
14. Cyclopropane [usp:inn]
15. Einecs 200-847-8
16. Rc 270
17. Un1027
18. Cyclopropnane
19. Unii-99tb643425
20. Cyclopropane [anaesthetics, Volatile]
21. Cyclopropane, >=99%
22. Cyclopropane (usp/inn)
23. Cyclopropane [mi]
24. Cyclopropane [hsdb]
25. Cyclopropane [mart.]
26. Cyclopropane [who-dd]
27. Chembl1796999
28. Dtxsid4058786
29. Cyclopropane [usp Impurity]
30. Mfcd00001268
31. Akos015915611
32. Db13984
33. Un 1027
34. Cyclopropane [un1027] [flammable Gas]
35. D03627
36. Q80250
| Molecular Weight | 42.08 g/mol |
|---|---|
| Molecular Formula | C3H6 |
| XLogP3 | 1.6 |
| Hydrogen Bond Donor Count | 0 |
| Hydrogen Bond Acceptor Count | 0 |
| Rotatable Bond Count | 0 |
| Exact Mass | 42.0469501914 g/mol |
| Monoisotopic Mass | 42.0469501914 g/mol |
| Topological Polar Surface Area | 0 Ų |
| Heavy Atom Count | 3 |
| Formal Charge | 0 |
| Complexity | 4.8 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Anesthetics
National Library of Medicine's Medical Subject Headings online file (MeSH, 1999)
/FORMER USE:/WITH CYCLOPROPANE, THE MARGIN OF SAFETY IS FAIRLY WIDE, 13% TO 20% PRODUCING ANESTHESIA AND 40% RESPIRATORY ARREST.
Thienes, C., and T.J. Haley. Clinical Toxicology. 5th ed. Philadelphia: Lea and Febiger, 1972., p. 54
/FORMER USE:/ IT IS THE MOST POTENT OF THE ANESTHETIC GASES, BEING APPROX FIVE TIMES AS POTENT AS ETHYLENE & SEVEN TIMES AS POTENT AS NITROUS OXIDE.
Osol, A. and J.E. Hoover, et al. (eds.). Remington's Pharmaceutical Sciences. 15th ed. Easton, Pennsylvania: Mack Publishing Co., 1975., p. 980
/FORMER USE:/ MEDICATION (VET): INHALATION ANESTHETIC
Budavari, S. (ed.). The Merck Index - An Encyclopedia of Chemicals, Drugs, and Biologicals. Whitehouse Station, NJ: Merck and Co., Inc., 1996., p. 464
SECOND GAS EFFECT. ...INCREASED INSPIRATORY VOL CARRIES WITH IT ANY OTHER GAS GIVEN CONCOMITANTLY AND HENCE WILL ACCELERATE THE RISE OF ALVEOLAR CONCN OF SECOND GAS.
LaDu, B.N., H.G. Mandel, and E.L. Way. Fundamentals of Drug Metabolism and Disposition. Baltimore: Williams and Wilkins, 1971., p. 113
CYCLOPROPANE CAUSES NEONATAL DEPRESSION.
LaDu, B.N., H.G. Mandel, and E.L. Way. Fundamentals of Drug Metabolism and Disposition. Baltimore: Williams and Wilkins, 1971., p. 100
POSTANESTHETIC HYPOTENSION, DELIRIUM AND HEADACHE ARE MORE FREQUENT THAN AFTER THE USE OF OTHER AGENTS.
Goodman, L.S., and A. G. Gilman. (eds.). The Pharmacological Basis of Therapeutics. 4th ed. New York: Macmillan Co., 1970., p. 77
PUPILLARY SIZE TENDS TO INCREASE BOTH DURING PROFOUND ANESTHESIA & DURING EMERGENCE... LACRIMATION MAY OCCUR... EYEBALL MOVEMENTS USUALLY OCCUR IN PLANE 1... AT PROFOUND LEVELS PROPTOSIS IS COMMON. ... ARTERIAL BLOOD PRESSURE IS USUALLY LITTLE AFFECTED BY CONCN OF CYCLOPROPANE CAUSING SURGICAL ANESTHESIA, ALTHOUGH SEVERE REDN MAY OCCUR WHEN HEMORRHAGE, MYOCARDIAL DISEASE, OR SEPSIS IS PRESENT.
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 85
For more Drug Warnings (Complete) data for CYCLOPROPANE (7 total), please visit the HSDB record page.
Anesthetics
Agents capable of inducing a total or partial loss of sensation, especially tactile sensation and pain. They may act to induce general ANESTHESIA, in which an unconscious state is achieved, or may act locally to induce numbness or lack of sensation at a targeted site. (See all compounds classified as Anesthetics.)
CYCLOPROPANE IS RAPIDLY ABSORBED AND ALMOST ENTIRELY ELIMINATED BY WAY OF THE LUNGS; A SMALL AMT DIFFUSES THROUGH THE SKIN AND AN ADDITIONAL SMALL AMOUNT (ROUGHLY 0.5%) IS METABOLIZED IN THE BODY...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 87
...A SMALL AMT (ROUGHLY 0.5%) IS METABOLIZED IN THE BODY AND EXCRETED AS CARBON DIOXIDE AND WATER...
Goodman, L.S., and A. Gilman. (eds.) The Pharmacological Basis of Therapeutics. 5th ed. New York: Macmillan Publishing Co., Inc., 1975., p. 87
NON-STEADY STATE METABOLISM OF INHALATION ANESTHETICS DURING ANESTHESIA & RECOVERY WAS SIMULATED WITH LINEAR & NON-LINEAR WHOLE BODY COMPARTMENTAL MODEL. THESE TWO MODELS WERE STUDIED FOR NINE ANESTHETICS DURING 1 MINUTE ALVEOLAR CONCN ANESTHESIA LASTING 1, 4 AND 8 HR AND RECOVERY FROM 5 TO 10 DAYS. BOTH MODELS DEMONSTRATED SIGNIFICANT METABOLISM FOR SEVERAL DAYS FOLLOWING ANESTHESIA. FOR THE LINEAR MODEL, BOTH THE PERCENTAGE AND THE MOLAR QUANTITY OF ANESTHETIC METABOLIZED INCREASED WITH INCREASED DURATION OF ANESTHESIA, INCREASED ANESTHETIC FAT SOLUBILITY AND INCREASED ASSUMED RATE OF HEPATIC METABOLISM. FOR THE NON-LINEAR MODEL, THE DURATION OF ANESTHESIA HAD LITTLE EFFECT ON THE PERCENTAGE METABOLIZED BUT DEMONSTRATED INCREASED MOLAR QUANTITIES OF ANESTHETIC METABOLIZED WITH INCREASED DURATION OF ANESTHESIA AND INCREASED FAT SOLUBILITY.
PMID:836747 FEINGOLD A, HOLADAY DA; BR J ANAESTH 49 (2): 155-62 (1977)
The effect of several inhalation and iv anesthetics, alone or in combination, on brain electric activity during evoked cortical response was studied in rats. All of the anesthetics affect the evoked sensory response in a manner which suggests a common site of anesthetic action, namely, the perturbation of normal modulation exerted upon the ventrobasal thalamus by the thalamic reticular nucleus which is remarkably susceptible to the action of these agents.
Angel A, Gratton DA; Prog Anesthesiol 3 (Pharmacol Basis Anesthesiol): 1-12 (1983)
API SUPPLIERS
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
USDMF
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]API Reference Price
API/FDF Prices: Book a Demo to explore the features and consider upgrading later
API Imports and Exports
| Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
|---|
Upgrade, download data, analyse, strategize, subscribe with us 
ABOUT THIS PAGE
54
PharmaCompass offers a list of Cyclopropane API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Cyclopropane manufacturer or Cyclopropane supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Cyclopropane manufacturer or Cyclopropane supplier.
PharmaCompass also assists you with knowing the Cyclopropane API Price utilized in the formulation of products. Cyclopropane API Price is not always fixed or binding as the Cyclopropane Price is obtained through a variety of data sources. The Cyclopropane Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A UN1027 manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of UN1027, including repackagers and relabelers. The FDA regulates UN1027 manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. UN1027 API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A UN1027 supplier is an individual or a company that provides UN1027 active pharmaceutical ingredient (API) or UN1027 finished formulations upon request. The UN1027 suppliers may include UN1027 API manufacturers, exporters, distributors and traders.
click here to find a list of UN1027 suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A UN1027 DMF (Drug Master File) is a document detailing the whole manufacturing process of UN1027 active pharmaceutical ingredient (API) in detail. Different forms of UN1027 DMFs exist exist since differing nations have different regulations, such as UN1027 USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A UN1027 DMF submitted to regulatory agencies in the US is known as a USDMF. UN1027 USDMF includes data on UN1027's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The UN1027 USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of UN1027 suppliers with USDMF on PharmaCompass.
UN1027 Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of UN1027 GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right UN1027 GMP manufacturer or UN1027 GMP API supplier for your needs.
A UN1027 CoA (Certificate of Analysis) is a formal document that attests to UN1027's compliance with UN1027 specifications and serves as a tool for batch-level quality control.
UN1027 CoA mostly includes findings from lab analyses of a specific batch. For each UN1027 CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
UN1027 may be tested according to a variety of international standards, such as European Pharmacopoeia (UN1027 EP), UN1027 JP (Japanese Pharmacopeia) and the US Pharmacopoeia (UN1027 USP).
